In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

While most of the cash for Swiss biotech firms comes from outside the country, around 20% is provided by Swiss entities. Scrip spoke with two of these home-grown supporters of life sciences innovation about the move from academia to industry and their respective investment strategies.

Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.

The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.